HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.

By M. Owens, B. Horten, M. D. Da Silva. Clinical Breast Cancer, 2004

639 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 (2009, methodology): “ERBB2 and ERBB3 in human tumorigenesis ERBB2 amplification and overexpression have been reported in a number of human tumours, including in 18–25% of human breast cancers, depending on the diagnostic technique used and other factor”
Iron and iron-oxide magnetic nanoparticles as signal-amplification elements in electrochemical biosensing (2015, background): “Human epidermal growth factor receptor 2 (HER2), as a key prognostic marker [48], is over-expressed in 10–25% of breast cancers [49], which are some of themost commonmalignant types of tumors in women [50].”
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. (2006, background): “The equivocal range for IHC consists of samples scored 2 , and this may include up to 15% of samples.(29) An equivocal result (2 ) is complete membrane staining that is either nonuniform or weak in intensity but with obvious circumferential distribution in at least 10% of cells.”